# **NIH funding opportunities**

### 16 September 2024 (#27)



Confirm your intent to apply ASAP, but not later than 60 days before the submission date.



#### See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

1) Generic Grant Writing Workshop and then the

2) NIH Grant Writing Workshop

To prepare an application can take 4-18 months.

From submission to receiving a Notice of Award can take 10 months

#### **Important Notices**

<u>NOT-DK-24-036</u> Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed). The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on Type 1 Diabetic (T1D) nephropathy. Estimated Publication Date September 30, 2024.

#### **Parent Announcements**

<u>NOT-OD-24-099</u> Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates Modified Expiration Date: January 8, 2025

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

#### **Notice of Special Interest (NOSI)**

**NOT-DA-26-003** Consequences of Prenatal Fentanyl Exposure. The opioid epidemic has led to a rise in opioid misuse among pregnant women posing unique challenges and risks to maternal and especially fetal health. Little is known

about prenatal effects of fentanyl, a synthetic opioid increasingly present in unregulated drug supply and increasingly misused during pregnancy. The purpose of this NOSI is to promote research on neurobehavioral, neurological, and potential teratogenic effects of prenatal fentanyl exposure in humans and in animal models. This notice applies to due dates on or after June 5, 2025 and subsequent receipt dates through September 8, 2028.

<u>NOT-DA-26-005</u> Application of Artificial Intelligence in Treatment Development for Substance Use Disorders. The proliferation of large-scale databases and biomedical repositories, accelerated by the transition to electronic health records and calls for increased data sharing, marks a significant shift in biomedical research. The purpose of this NOSI) is to elicit projects that would leverage the power of generative AI/ML and predictive models to accelerate medication discovery and development for treatment of SUDs while reducing the risk of failure.

**NOT-MH-24-380 Developing and Delivering Feasible Screening Methods and Tools for Eating Disorders**. The National Institute of Mental Health (NIMH) is issuing this Notice of Special Interest (NOSI) to encourage applications that investigate the development and delivery of screening methods for subthreshold and diagnosable eating disorders in naturalistic settings for children, adolescents, and adults. An emphasis is placed on research that seeks to develop and test low-burden, feasible screening methods, addresses inequities in detection among populations with health disparities, utilizes existing setting staff and/or lay/alternate providers to aid in screening efforts, aims to quantify the resources necessary to implement these approaches, and/or proposes to identify and address factors that hinder/facilitate implementation and scale-up. This notice applies to due dates on or after October 15, 2024, and subsequent receipt dates through May 8, 2027.

## Notice of Funding Opportunity (NOFO)

<u>RFA-DA-25-073</u> Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed). This NOFO will support highrisk, high-impact studies that 1) develop or apply novel tools or technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration and characterization of signaling pathways that are involved in central nervous system (CNS) HIV establishment and expansion. The NOFO aims to promote milestone-driven research to investigate the underlying molecular mechanisms by which HIV infection is initiated, established, and maintained in the CNS and to determine how addictive substances modulate HIV infection, latency and the size and persistence of CNS HIV reservoirs.

**Date:** August 14, 2025. All applications are due by 5:00 PM local time of applicant organization. Letter of Intent Due Date July 14, 2025.

**Budget:** NIDA intends to support up to three awards, corresponding to a total of \$2,000,000 in FY 2026. Applications may not request more than \$700K direct costs for any single year. The maximum project period is 5 years.

Faculty of Medicine and Health Sciences

**Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO)** 009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.

Enquiries: <a href="mailto:fmhsgmo@sun.ac.za">fmhsgmo@sun.ac.za</a>

Add "Interest in NIH opportunity" in the subject line.

Add the notice number with hyperlink in the text of the email.